QLS-1209

N/A

Report date: 2025/12/22 17:22:43
NME

Base Information

Drug NameQLS-1209
Drug Alias NameQLS1209QLS-1209
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitors
TargetsMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A